Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Caribou Biosciences Analyst Ratings and Price Targets | NASDAQ:CRBU | Benzinga
Caribou Biosciences Inc has a consensus price target of $14.17 based on the ratings of 7 analysts. The high is $32 issued by Oppenheimer on March 10, 2023. The low is $3 issued by HC Wainwright & Co. on April 28, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and B of A Securities on April 28, 2025, March 19, 2025, and January 7, 2025, respectively. With an average price target of $7.67 between HC Wainwright & Co., HC Wainwright & Co., and B of A Securities, there's an implied 797.42% upside for Caribou Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
B of A Securities
Citigroup
RBC Capital
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Caribou Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/28/2025 | Buy Now | 251.16% | HC Wainwright & Co. | Robert Burns43% | $9 → $3 | Maintains | Buy | Get Alert |
| 03/19/2025 | Buy Now | 953.49% | HC Wainwright & Co. | Robert Burns43% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 01/07/2025 | Buy Now | 1187.6% | B of A Securities | Alec Stranahan33% | $13 → $11 | Maintains | Buy | Get Alert |
| 11/26/2024 | Buy Now | 602.33% | Citigroup | Yigal Nochomovitz53% | $30 → $6 | Maintains | Buy | Get Alert |
| 11/15/2024 | Buy Now | 953.49% | HC Wainwright & Co. | Robert Burns43% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 09/03/2024 | Buy Now | 953.49% | HC Wainwright & Co. | Robert Burns43% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2024 | Buy Now | 953.49% | HC Wainwright & Co. | Robert Burns43% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 1538.77% | RBC Capital | Luca Issi40% | $14 → $14 | Reiterates | Outperform → Outperform | Get Alert |
| 07/17/2024 | Buy Now | 953.49% | HC Wainwright & Co. | Robert Burns43% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 06/04/2024 | Buy Now | 953.49% | HC Wainwright & Co. | Robert Burns43% | $24 → $9 | Maintains | Buy | Get Alert |
| 05/16/2024 | Buy Now | 2124.04% | Truist Securities | Asthika Goonewardene41% | $19 → $19 | Maintains | Buy | Get Alert |
| 05/13/2024 | Buy Now | 2709.32% | HC Wainwright & Co. | Robert Burns43% | $24 → $24 | Reiterates | Buy → Buy | Get Alert |
| 03/19/2024 | Buy Now | 2709.32% | HC Wainwright & Co. | Robert Burns43% | $23 → $24 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 2124.04% | RBC Capital | Luca Issi40% | $19 → $19 | Reiterates | Outperform → Outperform | Get Alert |
| 11/08/2023 | Buy Now | — | Cantor Fitzgerald | Rick Bienkowski27% | — | Initiates | → Neutral | Get Alert |
| 07/26/2023 | Buy Now | 2592.26% | HC Wainwright & Co. | Robert Burns43% | $25 → $23 | Maintains | Buy | Get Alert |
| 07/14/2023 | Buy Now | 2592.26% | Truist Securities | Asthika Goonewardene41% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 2592.26% | Truist Securities | Asthika Goonewardene41% | → $23 | Initiates | → Buy | Get Alert |
| 05/10/2023 | Buy Now | 2826.37% | HC Wainwright & Co. | Robert Burns43% | $26 → $25 | Maintains | Buy | Get Alert |
| 03/14/2023 | Buy Now | 2943.43% | HC Wainwright & Co. | Robert Burns43% | $27 → $26 | Maintains | Buy | Get Alert |
| 03/10/2023 | Buy Now | 2124.04% | RBC Capital | Luca Issi40% | → $19 | Reiterates | → Outperform | Get Alert |
| 03/10/2023 | Buy Now | 3645.76% | Oppenheimer | Mark Breidenbach46% | $36 → $32 | Maintains | Outperform | Get Alert |
| 08/29/2022 | Buy Now | 4348.09% | Citigroup | Yigal Nochomovitz53% | $39 → $38 | Maintains | Buy | Get Alert |
| 08/18/2022 | Buy Now | 3060.48% | HC Wainwright & Co. | Robert Burns43% | $28 → $27 | Maintains | Buy | Get Alert |
| 08/10/2022 | Buy Now | 2124.04% | RBC Capital | Luca Issi40% | $22 → $19 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Caribou Biosciences (CRBU) stock?
The latest price target for Caribou Biosciences (NASDAQ:CRBU) was reported by HC Wainwright & Co. on April 28, 2025. The analyst firm set a price target for $3.00 expecting CRBU to rise to within 12 months (a possible 251.16% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Caribou Biosciences (CRBU)?
The latest analyst rating for Caribou Biosciences (NASDAQ:CRBU) was provided by HC Wainwright & Co., and Caribou Biosciences maintained their buy rating.
When was the last upgrade for Caribou Biosciences (CRBU)?
There is no last upgrade for Caribou Biosciences
When was the last downgrade for Caribou Biosciences (CRBU)?
There is no last downgrade for Caribou Biosciences.
When is the next analyst rating going to be posted or updated for Caribou Biosciences (CRBU)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Caribou Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Caribou Biosciences was filed on April 28, 2025 so you should expect the next rating to be made available sometime around April 28, 2026.
Is the Analyst Rating Caribou Biosciences (CRBU) correct?
While ratings are subjective and will change, the latest Caribou Biosciences (CRBU) rating was a maintained with a price target of $9.00 to $3.00. The current price Caribou Biosciences (CRBU) is trading at is $0.85, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
